Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Umecrine Cognition AB is navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, SHIAO, REI TSANG, who also serves as the busiest examiner for the portfolio. SHIAO, REI TSANG is currently managing the pending office action.
The concentration of the current portfolio within a single art unit and under a single examiner suggests a highly focused prosecution strategy. Because there is only 1 pending office action, the company's immediate success in the Biotechnology & Pharmaceuticals sector depends entirely on the review by SHIAO, REI TSANG. This arrangement provides no opportunity for internal comparison between different examiners or art units.
Practitioners should prioritize understanding the specific examination style of SHIAO, REI TSANG, as they hold the entirety of the company's pending workload. The 1 distinct art unit involved will define the technical standards and procedural expectations for this matter. With only a single active case, the company can dedicate its full attention to the specific requirements of this examiner in the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287329 | GOLEXANOLONE FOR USE IN THE TREATMENT OF FATIGUE OR COGNITIVE IMPAIRMENT IN LIVER DISEASE PATIENTS | SHIAO, REI TSANG | 1691 | DP | Final Rejection | 24d overdue | Pending | Oct 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial